Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB
Bank of America Corp DE significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 283.2% in the first quarter, acquiring 370,319 additional shares. The firm now holds 501,086 shares valued at approximately $27.8 million, representing 1.72% of the company. Other institutional investors, including Affinity Asset Advisors and Royal Bank of Canada, also boosted their positions, while analysts maintain a "Moderate Buy" consensus rating for AnaptysBio with an average price target of $82.00.
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The shares are held in a managed account of Point72 Associates II, LLC, with Sirenia and Mr. Silverstein exercising shared voting and dispositive power.
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings?
AnaptysBio (ANAB) has experienced significant share price swings but is considered undervalued by analysts and intrinsic value estimates, trading at a discount despite strong longer-term momentum. The company, focused on immunology therapeutics, is projected to have a fair value of $90 due to rising royalty streams, a future revenue doubling from a loan expiration, and potential upside from a lawsuit. However, investors are cautioned to consider risks like the outcome of GSK litigation and potential deviations in royalty and clinical expectations.
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com
AnaptysBio, now operating as Anaptys, is set to release its Q2 earnings, marking its first full quarter as a pure-play royalty management company after spinning off its drug development operations. Analysts predict a loss of 13 cents per share on $20.2 million in revenue, a significant improvement in losses but a revenue decline from the previous quarter. Investors will closely watch Jemperli royalty revenue trajectory and operating margin execution to see if the simplified model can deliver promised profitability and stability despite wavering analyst confidence and potential quarterly volatility.
AnaptysBio (ANAB) awards CEO 53,334 performance stock units
AnaptysBio (ANAB) has awarded its President and CEO, Daniel Faga, 53,334 performance stock units (PSUs). These PSUs were granted after meeting specific performance criteria and will vest over two years, with 50% vesting on March 12, 2027, and the remaining 50% on March 12, 2028, contingent on his continued employment. Each PSU represents one share of common stock.
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO
AnaptysBio (NASDAQ: ANAB) has awarded 16,667 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul. These PSUs were granted on March 12, 2026, after achieving certified performance criteria, with each unit representing a right to one share of common stock. The units will vest 50% on March 12, 2027, and 50% on March 12, 2028, contingent on Lizzul's continued employment.
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility?
AnaptysBio, now operating as Anaptys, is set to report its Q2 results as a pure-play royalty management company after spinning off its drug development operations. Analysts project a loss of 13 cents per share on $20.2 million in revenue, with a significant improvement in EPS despite an expected revenue decline. Investors will focus on Jemperli royalty revenue trajectory, operating margin execution, and potential variability in royalty recognition.
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $82.00. Despite missing quarterly earnings per share estimates, the company exceeded revenue expectations. Several institutions have recently increased their holdings in AnaptysBio stock.
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
AnaptysBio (ANAB) has entered a key post-trial phase in its legal dispute with Tesaro and GlaxoSmithKline, involving allegations of material breach of contract and tortious interference. Following a trial in July 2026, a schedule for post-trial briefing and argument has been set, with key dates extending through October 2026 for final arguments. Analysts currently rate ANAB with a "Buy" and a $75.00 price target, though TipRanks' AI Analyst, Spark, notes a "Neutral" outlook due to financial risks despite operational improvements.
AnaptysBio and Tesaro set post-trial briefing schedule after July 2026 trial
AnaptysBio announced the post-trial briefing schedule following its July 2026 litigation with Tesaro and GlaxoSmithKline. A Joint Stipulation was granted by the Court, setting deadlines for briefs, with AnaptysBio filing its opening brief by August 21, 2026. Oral arguments are scheduled for October 20, 2026, moving the case towards a final court decision.
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis
AnaptysBio Inc (ANAB) has a strong financial score of 7.86, placing it high within the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue and net profit experienced year-over-year decreases of 7.98% and 34.47% respectively. The analysis also covers various aspects of its financial performance like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns.
AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20
AnaptysBio has announced the dates for post-trial briefings in its Delaware Chancery Court dispute with Tesaro and GlaxoSmithKline regarding a collaboration license. AnaptysBio is seeking a declaration that Tesaro materially breached the agreement and alleges GlaxoSmithKline tortiously interfered. The consolidated trial concluded in July 2026, with post-trial arguments scheduled for October 20, 2026.
Arrowstreet Capital Limited Partnership Sells 67,624 Shares of AnaptysBio, Inc. $ANAB
Arrowstreet Capital Limited Partnership reduced its stake in AnaptysBio, Inc. by 12.1% in the first quarter, selling 67,624 shares and retaining 492,120 shares valued at approximately $27.3 million. AnaptysBio reported a significant quarterly loss per share of $1.84, missing analyst expectations, despite revenue exceeding estimates. The company currently has a "Moderate Buy" consensus rating from analysts with an average price target of $82.
ANAB|AnaptysBio Inc|Price:52.220|Chg%:+0.110
This article provides a comprehensive stock analysis of AnaptysBio Inc (ANAB) by TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it has received "Buy" ratings from multiple analysts. Despite recent weak market performance, its stock is trending sideways between support and resistance levels, making it suitable for range-bound swing trading.
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for AnaptysBio Inc (ANAB), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 5.15, ranking 50 out of 384 in its industry, and a beta value of 0.89, indicating it tends to underperform in up markets but decline less in down markets. Key metrics like VaR, maximum drawdown, volatility, return, Sharpe ratio, and liquidity are presented to illustrate the stock's risk profile.
AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of AnaptysBio Inc (ANAB), highlighting its current valuation score of 9.19 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -51.12, and indicates that P/B, P/S, and P/CF ratios have not yet been disclosed. The analysis emphasizes that relevant data for these metrics are awaiting disclosure from the company.
AnaptysBio (ANAB) Projected to Post Earnings on Wednesday
AnaptysBio (ANAB) is expected to announce its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.1252 per share and revenue of $17.3340 million. The company missed earnings estimates in the previous quarter but exceeded revenue forecasts. Despite recent price performance below key moving averages, ANAB holds a consensus “Moderate Buy” rating and an $82 price target from analysts.
AnaptysBio shifts to royalty management, focusing on growing Jemperli royalties from GSK.
AnaptysBio has transitioned into a royalty management company, concentrating on Jemperli, an oncology drug commercialized by GSK, after eliminating R&D expenses. The company aims for a 95% EBIT margin with over $140 million in net cash, anticipating increased Jemperli royalties and benefiting from high-margin streams post-2027. This strategy is supported by positive trial data, potential label expansions for Jemperli, and a $100 million share buyback plan.
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB
Eversept Partners LP significantly reduced its stake in AnaptysBio, Inc. by 77.6% in the first quarter, selling over 93,000 shares and retaining a smaller position valued at $1.5 million. This move comes despite AnaptysBio reporting revenue that exceeded analyst expectations, though it missed on earnings per share. The company still holds a "Moderate Buy" consensus rating from analysts with an average price target of $82.
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of AnaptysBio Inc (ANAB), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between resistance at $66.44 and support at $45.24, suitable for range-bound swing trading. Technical indicators show a mixed signal with more sells than buys, while moving averages largely indicate a sell signal.
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of AnaptysBio Inc's (ANAB) shareholder structure, listing major shareholders by proportion, categorizing shareholders by type, and detailing institutional shareholding data over several quarters. It also includes information on shareholder activity and related ETFs.
ANAB|AnaptysBio Inc|Price:54.586|Chg%:+0.436
AnaptysBio Inc. is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. The company's lead program, Rosnilimab, is in Phase IIb trials for rheumatoid arthritis and Phase II for ulcerative colitis. Detailed company information, including executives, financials, and institutional shareholdings, are provided, showing a recent increase in institutional investment.
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB
First Light Asset Management LLC reduced its stake in AnaptysBio Inc. by 12.5% in the first quarter, selling over 80,000 shares but still maintaining a significant holding. Meanwhile, several other institutional investors, including Affinity Asset Advisors and JPMorgan Chase, substantially increased their positions in the biotechnology company. Despite AnaptysBio missing earnings estimates with a loss of $1.84 per share, analysts maintain a "Moderate Buy" consensus with an average price target of $82.
ANAB Cash Flow Statement
This article provides the quarterly and annual cash flow statements for AnaptysBio Inc (ANAB), detailing operating, investing, and financing cash flows from FY2015Q1 to FY2026Q1. It includes specific figures for net income, capital expenditures, and free cash flow, along with year-over-year changes. The document also offers FAQs explaining key cash flow metrics like operating, investing, financing, and free cash flow, and their relevance to ANAB's financial health.
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760
AnaptysBio Inc. (ANAB) closed at $54.150, down 1.38%, with a high growth potential and sound fundamentals, yet its stock price is expected to trend downwards in the medium term. The company is clinical-stage, specializing in immunology therapeutics, with its lead program Rosnilimab currently in Phase IIb and Phase II trials. Analysts have a "Buy" rating with an average target price of $88.80, indicating a potential 61.72% upside.
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB
HSBC Holdings PLC has acquired a new stake in AnaptysBio, Inc., purchasing 125,717 shares valued at approximately $7.1 million, representing about 0.43% of the company. This comes despite AnaptysBio reporting a larger-than-expected quarterly loss, though revenue exceeded estimates. Analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $82, and the company recently authorized a significant share buyback plan.
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million.
AnaptysBio, Inc.'s equity buyback program, which was announced on March 24, 2025, has concluded. The company repurchased 3,444,079 shares, accounting for 11.5% of its equity, at a total cost of $68.63 million. The plan officially expired on March 31, 2026.
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6% - Here's What Happened
AnaptysBio (NASDAQ:ANAB) stock rose 5.6% on Thursday, trading as high as $55.94 with closing near $55.57, though with trading volume significantly lower than average. Analyst sentiment is mixed, leaning positive, with a consensus "Moderate Buy" rating and a price target of $81.82, despite recent downgrades. The company's recent earnings report showed a miss on EPS but beat revenue estimates, and a $100 million stock repurchase authorization suggests management believes the stock is undervalued.
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
H.C. Wainwright has reiterated its Buy rating for AnaptysBio (ANAB.US) and maintained its target price at $95. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
High Growth Tech Stocks In The US Market
The U.S. market, despite a recent 1.4% decline, has seen a 17% rise over the past year with an anticipated 18% annual earnings growth. This article identifies top high-growth tech stocks, highlighting companies like Ardelyx, AnaptysBio, and Syndax Pharmaceuticals, which demonstrate strong revenue expansion potential and innovation, particularly in biopharmaceuticals. These companies are poised for significant future growth due to their specialized products and strategic financial maneuvers.
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?
AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current price of $62.51, the stock appears undervalued, largely factoring in a favorable resolution to its royalty dispute or a strong ongoing royalty stream. Investors are advised to consider the company's royalty strength and legal outcomes, while also looking into broader healthcare and undervalued stock opportunities.
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10%
AnaptysBio (ANAB) shares fell by 10.8% on July 15, 2026, closing at $55.76, amidst broader market volatility and investor caution in the biotechnology sector. The company, a clinical-stage biotech developing antibody product candidates, has a market capitalization of $1.67 billion and a GF Score of 66/100, indicating moderate long-term return potential despite challenges in profitability and significant insider selling. Investors are advised to monitor clinical trial results and market trends.
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75
Barclays has reiterated its Buy rating on AnaptysBio (ANAB.US), maintaining a target price of $75. This continued positive outlook suggests the firm sees potential upside for the biotechnology company's stock.
AnaptysBio (NASDAQ:ANAB) Shares Down 7% - Time to Sell?
AnaptysBio (NASDAQ:ANAB) shares dropped 7% in Tuesday trading, hitting an intraday low of $65.76. Despite a wider-than-expected Q1 loss, analysts maintain a "Moderate Buy" rating with an average price target of $81.82, and the company has authorized a $100 billion stock repurchase program. Institutional investors have also increased their holdings in the biotechnology company.
Form 144 ANAPTYSBIO For: 13 July By Investing.com
This article reports on a Form 144 filing for ANAPTYSBIO on July 13. It is a brief, factual announcement from Investing.com, providing no additional details beyond the filing date and company name. The article's content is minimal, serving primarily as an informational update.
Form 144 ANAPTYSBIO For: 13 July By Investing.com
This article announces the filing of Form 144 for ANAPTYSBIO on July 13. Form 144 is a notice of the intent to sell restricted securities. The article provides only this financial event without further details.
AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise
JOE ANTHONY WARE, an insider at AnaptysBio (ANAB), has filed a Form 144 to sell 10,694 shares of common stock with an aggregate market value of $718,333.09. These shares are related to a stock option exercise and are expected to be sold on or after July 13, 2026, on NASDAQ. This follows a previous sale of 6,030 shares on June 30, 2026, bringing in $408,773.70.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received a "Moderate Buy" consensus recommendation from thirteen brokerages, with an average 12-month price target of $81.82. Analyst ratings have been mixed, with some price target increases and some downgrades, indicating ongoing debate about the stock's short-term prospects. Despite reporting a wider-than-expected loss per share, the company's revenue beat estimates, and it has authorized a significant stock repurchase plan, suggesting management believes the shares are undervalued.
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base?
AnaptysBio (ANAB) was removed from several Russell indices in June 2026, which may impact its short-term trading liquidity and passive fund ownership. Despite this, the core investment thesis remains centered on its immunology pipeline and collaborations, with ongoing litigation and capital allocation decisions being more significant drivers. Investors should also consider the wide disagreement among fair value estimates and potential for further downside despite recent price retreat.
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base?
AnaptysBio (ANAB) was removed from several Russell indices in June 2026, which could affect its trading liquidity and passive fund ownership. Despite this, the core investment thesis remains focused on its immunology pipeline and collaborations. The article suggests that while the removal adds an element of uncertainty, the company's valuation, litigation outcomes, and capital allocation strategies are more significant drivers for active investors.
AnaptysBio, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of AnaptysBio, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategic decisions. It highlights key events such as earnings reports, corporate presentations, and conference transcripts, detailing the company's planned spin-off into biopharma and royalty entities, Jemperli royalty growth, and advancement of its clinical pipeline. Investors can use these resources to inform their investment decisions regarding ANAPTYSBIO, INC.
AnaptysBio, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of financial disclosures and regulatory filings for AnaptysBio, Inc. The documents detail the company's strategic decisions, including its planned spin-off into biopharma and royalty entities, quarterly earnings, and presentations from various healthcare conferences, offering insights into its performance, pipeline advancements, and future outlook. Key themes include the growth of Jemperli royalties and progress in clinical trials for immunology assets.
[144] ANAPTYSBIO, INC SEC Filing
This article details an SEC Form 144 filing by AnaptysBio, Inc. (ANAB) concerning a proposed sale of securities. The document indicates a neutral filing impact and sentiment, outlining the filer and issuer information, as well as details about the common stock to be sold by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also includes information on the acquisition of these securities and states that no securities were sold in the past three months for the account of the person described.
Enterprise value to revenue forward of AnaptysBio, Inc. – NASDAQ:ANAB
This article provides the enterprise value to revenue forward for AnaptysBio, Inc. (NASDAQ: ANAB). It presents a financial metric related to the company's valuation, indicating its enterprise value relative to its future anticipated revenue. The information is sourced from TradingView, focusing on the financial overview of the biotechnology company.
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?
AnaptysBio (ANAB) was recently removed from several Russell indices and entered a one-year sublease agreement for its San Diego facility. These actions suggest a strategic shift involving optimized real estate commitments and a reframing of its investment narrative. Investors should consider how these developments, alongside ongoing restructuring, clinical readouts, and litigation, influence the company's future value.
Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB
The article focuses on the "Price to book forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It provides a view of this financial indicator on the TradingView platform, noting that the market is closed and no trades have occurred for the stock.
Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB
The article provides the "Enterprise value to EBITDA forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It appears to be a financial data snippet from TradingView, which offers various market tools and data for stocks, including detailed financial information.
Form 144 ANAPTYSBIO For: 29 June By Investing.com
This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on June 29. Form 144 is filed with the SEC when company insiders intend to sell restricted or controlled securities. The article provides the title, date, and company, indicating a standard regulatory filing notification.
Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB)
An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB) has filed a Form 144 to sell 9,476 shares acquired via a stock option exercise on June 29, 2026. The filing also details multiple common stock dispositions by Dennis Mulroy throughout May and June 2026, including specific share counts and gross proceeds from each sale. This indicates routine insider and affiliate transaction activity.
AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits
AnaptysBio (NASDAQ: ANAB) is holding its annual stockholders meeting on August 11, 2026, where key items for vote include the election of two Class III directors, ratification of KPMG LLP as the auditor, an advisory Say-on-Pay vote for executive compensation, and an amendment to its 2017 Equity Incentive Plan. The proposed amendment would extend the plan's term by 10 years and introduce compensation caps for non-employee directors, without increasing the current share reserve. As of June 22, 2026, 29,608,481 common shares are outstanding and eligible to vote.
